EGFR expression: Associations with outcome and clinicopathological variables in malignant pleural mesothelioma
- 31 December 2006
- journal article
- Published by Elsevier BV in Lung Cancer
- Vol. 54 (3), 399-407
- https://doi.org/10.1016/j.lungcan.2006.08.012
Abstract
No abstract availableThis publication has 40 references indexed in Scilit:
- EGFR overexpression in malignant pleural mesothelioma: An immunohistochemical and molecular study with clinico-pathological correlationsLung Cancer, 2006
- The selective epidermal growth factor receptor tyrosine kinase inhibitor PD153035 suppresses expression of prometastasis phenotypes in malignant pleural mesothelioma cells in vitroThe Journal of Thoracic and Cardiovascular Surgery, 2005
- Palliative surgical debulking in malignant mesothelioma Predictors of survival and symptom controlEuropean Journal of Cardio-Thoracic Surgery, 2001
- Anticancer therapy targeting the erbB family of receptor tyrosine kinasesSeminars in Oncology, 2001
- EGFR and cancer prognosisEuropean Journal of Cancer, 2001
- The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunitiesEuropean Journal of Cancer, 2001
- The erbB/HER type 1 tyrosine kinase receptor familyThe Journal of Pathology, 1998
- Epidermal growth factor receptor (EGFr) expression in non-small cell lung carcinomas correlates with metastatic involvement of hilar and mediastinal lymph nodes in the squamous subtypeEuropean Journal of Cancer, 1995
- Enhanced epidermal growth factor receptor synthesis in human squamous carcinoma cells exposed to low levels of oxygenInternational Journal of Cancer, 1992
- Epidermal growth factor and its receptorMolecular and Cellular Endocrinology, 1987